2023-505884-35-00RecruitingPhase 4
Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with long-acting Somatostatin Analogues – ATSA trial
Source: EU CTIS (euclinicaltrials.eu) · Last updated 17 Jun 2026
Brief summary (registry, in English)
The effect of continued LA-SSA use on the absorbed dose in tumor lesions during PRRT.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 34 (estimated)
- First submitted
- 12 Sept 2023
- Start date
- 17 Jun 2024
- Lead sponsor
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
- Diseases
- Neuroendocrine tumours
- EU CT number
- 2023-505884-35-00
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 34
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Other
- Not possible to discontinue LA-SSA for 4-6 weeks
- Use of short-acting somatostatin analogues
- Inability to comply to the study procedures
- Factors that might affect the biodistribution (for example, indication for furosemide directly after PRRT infusion, limited fluid intake, any renal catheters, etc.)
- Pregnancy and lactating female patients
Who the study is looking for
- Age ≥ 18 years
- Able to provide spoken and written informed consent for the trial
- Histopathological confirmed neuroendocrine tumor
- Fulfill the clinical criteria for PRRT
- At least one soft tissue lesion > 2 cm
- Aimed administered activity of 7400 MBq
- ECOG score (performance status) 0-2
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | Amsterdam | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.